Detection of Prostate Cancer Using Voided Urine

NCT ID: NCT04788277

Last Updated: 2025-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

675 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-26

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study collects urine from male patients seen at the urology clinic to detect prostate cancer cells, shed in voided urine, using the optical imaging method developed in the laboratory, which targets certain biomarkers expressed on prostate cancer cells. The information learned from this study may allow researchers develop a simple diagnostic test for the management of those patients who have elevated prostate specific antigen (PSA) and are suspected to have prostate cancer. It may also help researchers understand the genetic risk factors associated with prostate cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To detect prostate cancer cells, shed in voided urine, using the optical imaging method developed in our laboratory, which targets vasoactive intestinal polypeptide receptor 1 (VPAC1) receptors expressed on prostate cancer cells and validates the results with prevailing condition of the patients/volunteers and evaluate diagnostic accuracy.

SECONDARY OBJECTIVES:

I. To establish if the malignant cells as a percent of total cell shed in the urine.

II. To establish the fluorescence intensity around malignant cells. III. To establish if the VPAC protein quantity in shed malignant cells correlate with the aggressiveness of the disease.

OUTLINE:

Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (biospecimen collection)

Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of urine samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection

Undergo collection of urine samples

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biological Sample Collection Biospecimen Collected Specimen Collection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide signed and dated informed consent form
* Male
* Patients must be 50-70 years of age
* Willing to comply with all study procedures
* Prior to digital rectal exam (DRE)
* Patients with the diagnosis of prostate cancer (Cohort 1 N=150)

* Prior to radical prostatectomy/radiotherapy (XRT) or systemic therapy
* May be on active surveillance
* Patients with elevated PSA level but no know prostate cancer (Cohort 2 N=150)

* Diagnosis of BPH/lower urinary tract symptoms (LUTS)
* No prior diagnosis of prostate cancer
* Prior negative biopsy with PSA \> 1.5
* Without biopsy PSA \< 1.5
* Patients with normal PSA levels (Cohort 3 N=200)

* No documented history of BPH (no medical management or prior surgical treatment for BPH)
* PSA \< 1.5
* No documented history of prostate cancer
* No documented history of urothelial carcinoma
* Patients Pre DRE and Post DRE (Cohort 4 N=200)\*\*
* Patients on with a known Gleason Score (Cohort 5= 150)

Exclusion Criteria

• Patients under the age of 50
Minimum Eligible Age

50 Years

Maximum Eligible Age

79 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Thomas Jefferson University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Madhukar Thakur, MD

Role: PRINCIPAL_INVESTIGATOR

Thomas Jefferson University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Madhukar Thakur, MD

Role: CONTACT

215-503-7874

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Madhukar Thakur, MD

Role: primary

215-503-7874

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JT 15161

Identifier Type: OTHER

Identifier Source: secondary_id

20G.196

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Early Detection of Prostate Cancer
NCT04556916 RECRUITING NA
Predicting Prostate Cancer in Elderly Men
NCT04079699 NOT_YET_RECRUITING NA